p53 (2B2.68)

mouse

p53抗体(2B2.68)是小鼠单克隆IgG2a κ, 在21篇文献中引用，规格为200 µg/mlN-terminal抗原表位位于human来源的p53的11-25氨基酸残基之间推荐用于 human 来源的wild type and mutant p53 under denaturing and non-denaturing conditions WB, IP, IF, IHC(P) 和 FCM检测还可偶联琼脂糖 用于IP; 偶联HRP 的产品, 应用于WB, IHC(P)和ELISA; 偶联藻红蛋白 FITC 的产品, 应用于IF,IHC(P)和FCM还可偶联TRITC 用于IF, IHC(P) 和FCM可用于凝胶迁移和ChIP的TransCruz试剂(sc-71817 X, 200 µg/0.1 ml)看 p53 (DO-1): sc-126，可查看有标记的 p53 抗体，包括AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 和 790m-IgG Fc BP-HRP and m-IgG2a BP-HRP 是 p53 Antibody (2B2.68) for WB and IHC(P)首选应用二抗。这些试剂现在以套装形式提供p53 Antibody (2B2.68) (见下方订购信息). 查看产品引用文献(21) p53, a DNA-binding, oligomerization domain- and transcription activation domain-containing tumor suppressor, upregulates growth arrest and apoptosis-related genes in response to stress signals, thereby influencing programmed cell death, cell differentiation, and cell cycle control mechanisms. p53 localizes to the nucleus, yet can be chaperoned to the cytoplasm by the negative regulator, MDM2. MDM2 is an E3 ubiquitin ligase that is upregulated in the presence of active p53, where it poly-ubiquitinates p53 for proteasome targeting. p53 fluctuates between latent and active DNA-binding conformations and is differentially activated through posttranslational modifications, including phosphorylation and acetylation. Mutations in the DNA-binding domain (DBD) of p53, amino acids 110-286, can compromise energetically-favorable association with cis elements and are implicated in several human cancers.For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.

IGG-免疫球蛋白G型抗体

HumanTP53

7157